Evaluation of Factors Influencing Antibody Reduction for Development of Antibody Drug Conjugates

Evaluation of Factors Influencing Antibody Reduction for Development of Antibody Drug Conjugates Publisher Pubmed

Abdollahpouralitappeh M¹ ; Lotfinia M² ; Razavivakhshourpour S¹ ; Jahandideh S² ; Najminejad H¹ ; Sepehr KS³ ; Moazami R⁴ ; Shams E⁴ ; Habibianbouhi M⁵ ; Abolhassani M¹

Show Affiliations

1. Hybridoma Lab., Department OF Immunology, Pasteur Institute of Iran, Tehran, Iran
2. Department of Biochemistry, Pasteur Institute of Iran, Tehran, Iran
3. Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
4. Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
5. National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran

Source: Iranian Biomedical Journal Published:2017

Abstract

Background: Reduction/alkylation is one of the leading strategies for the development of antibody drug conjugates (ADCs). Precise control of the reduction process would not only yield a defined number of free thiols per antibody but also result in development of more homogenous conjugates. Methods: In the present study, we investigated the effect of various dithiothreitol (DTT) concentrations, temperature conditions, and DTT exposure times on antibody reduction. After antibody reduction, the Ellman's test and SDS-PAGE analysis were used to evaluate free thiols produced and confirm the reduction process, respectively. Results: DTT concentration seems to be a potential factor in the reduction process. Concentrations of 0.1, 1, 5, 10, 20, 50, and 100 mM DTT at 37°C for 30 minutes resulted in approximately 0.4, 1.2, 5.4, 7, 8, 8, and 8 thiols per antibody, respectively. Conclusion: Optimized site-specific conjugation can provide better process control and reproducibility for the development of disulfide-based ADCs. © 2017, Pasteur Institute of Iran. All rights reserved.

2. Development and Biological Assessment of Mmae-Trastuzumab Antibody–Drug Conjugates (Adcs), Breast Cancer (2021)

3. Adcs, As Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies, Current Drug Delivery (2020)

4. Synthesized Anti-Her2 Trastuzumab-Mcc-Dm1 Conjugate: An Evaluation of Efficacy and Cytotoxicity, Iranian Journal of Immunology (2023)

5. Maldi-Ms: A Rapid and Reliable Method for Drug-To-Antibody Ratio Determination of Antibody-Drug Conjugates, Iranian Biomedical Journal (2019)

6. Antibody-Drug Conjugates: Possibilities and Challenges, Avicenna Journal of Medical Biotechnology (2019)

7. Clinical Perspective: Antibody-Drug Conjugates for the Treatment of Her2-Positive Breast Cancer, Molecular Therapy (2023)

8. Antibody-Drug Therapeutic Conjugates: Potential of Antibody-Sirnas in Cancer Therapy, Journal of Cellular Physiology (2019)

Experts (# of related papers)

View all Related Experts

Mehdi Shafee Ardestani (1)

Alireza Foroumadi (1)

Style	Citing Format
MLA	Abdollahpouralitappeh M, et al.. "Evaluation of Factors Influencing Antibody Reduction for Development of Antibody Drug Conjugates." Iranian Biomedical Journal, vol. 21, no. 4, 2017, pp. 270-274.
APA	Abdollahpouralitappeh M, Lotfinia M, Razavivakhshourpour S, Jahandideh S, Najminejad H, Sepehr KS, Moazami R, Shams E, Habibianbouhi M, Abolhassani M (2017). Evaluation of Factors Influencing Antibody Reduction for Development of Antibody Drug Conjugates. Iranian Biomedical Journal, 21(4), 270-274.
Chicago	Abdollahpouralitappeh M, Lotfinia M, Razavivakhshourpour S, Jahandideh S, Najminejad H, Sepehr KS, Moazami R, Shams E, Habibianbouhi M, Abolhassani M. "Evaluation of Factors Influencing Antibody Reduction for Development of Antibody Drug Conjugates." Iranian Biomedical Journal 21, no. 4 (2017): 270-274.
Harvard	Abdollahpouralitappeh M et al. (2017) 'Evaluation of Factors Influencing Antibody Reduction for Development of Antibody Drug Conjugates', Iranian Biomedical Journal, 21(4), pp. 270-274.
Vancouver	Abdollahpouralitappeh M, Lotfinia M, Razavivakhshourpour S, Jahandideh S, Najminejad H, Sepehr KS, et al.. Evaluation of Factors Influencing Antibody Reduction for Development of Antibody Drug Conjugates. Iranian Biomedical Journal. 2017;21(4):270-274.
BibTex	@article{ author = {Abdollahpouralitappeh M and Lotfinia M and Razavivakhshourpour S and Jahandideh S and Najminejad H and Sepehr KS and Moazami R and Shams E and Habibianbouhi M and Abolhassani M}, title = {Evaluation of Factors Influencing Antibody Reduction for Development of Antibody Drug Conjugates}, journal = {Iranian Biomedical Journal}, volume = {21}, number = {4}, pages = {270-274}, year = {2017} }
RIS	TY - JOUR AU - Abdollahpouralitappeh M AU - Lotfinia M AU - Razavivakhshourpour S AU - Jahandideh S AU - Najminejad H AU - Sepehr KS AU - Moazami R AU - Shams E AU - Habibianbouhi M AU - Abolhassani M TI - Evaluation of Factors Influencing Antibody Reduction for Development of Antibody Drug Conjugates JO - Iranian Biomedical Journal VL - 21 IS - 4 SP - 270 EP - 274 PY - 2017 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract